CDK9-IN-9

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CDK9-IN-9 

CDK9-IN-9 (example 2) 是有效的，选择性 CDK9 抑制剂，IC50 为 1.8 nM。CDK9-IN-9 抑制 CDK2，IC50 为 155 nM。CDK9-IN-9 具有抗肿瘤活性。

CDK9-IN-9

CDK9-IN-9 Chemical Structure

CAS No. : 2246956-84-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CDK9-IN-9 (example 2) is a potent and selective CDK9 inhibitor with an IC50 of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC50 of 155 nM. CDK9-IN-9 has anti-cancer activity[1].

IC50 & Target[1]

CDK9

1.8 nM (IC50)

CDK2

155 nM (IC50)

体外研究
(In Vitro)

CDK9-IN-9 (example 2) inhibits the proliferation of HeLa, HeLa-MaTu-ADR, NCI-H460, DU145, Caco-2, B16F10, A2780 and MOLM-13 cells with IC50s of 4.4 nM, 5.3 nM, 9.2 nM, 4.5 nM, 8.4 nM, 1.2 nM, 1.2 nM, 2.0 nM, respectively[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

459.51

Formula

C22H23F2N5O2S
CAS 号

2246956-84-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ulrich LÜCKING, et al. Novel ptefb inhibiting macrocyclic compounds. WO2018177889A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务